ERBB2 and neoplasm: By contrast, significantly lower tumor uptake values (≈5% ID/g) were observed in two separate controls, namely, non-targeted C’ dots in BT-474 tumors and targeted C’ dots in HER2-negative tumors (Figure 7B,C).